Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04738630 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: HX008

Sponsor

Taizhou Hanzhong biomedical co. LTD